Quick Answer
ENANTA PHARMACEUTICALS INC reported Net Income Loss of -$81.89 million for the year ending 2025.
- ENANTA PHARMACEUTICALS INC showed an increase of +29.4% in Net Income Loss from 2024 to 2025.
- This data is from ENANTA PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on November 19, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: -$1.08 million | Q3 2016: -$1.80 million | Q4 2016: -$4.98 million | Q1 2017: -$5.39 million | Q2 2017: -$8.43 million | Q3 2017: $36.51 million | Q4 2017: $11.69 million | Q1 2018: $12.56 million | Q2 2018: $20.29 million | Q3 2018: $27.42 million | Q4 2018: $26.01 million | Q1 2019: $4.15 million | Q2 2019: $7.04 million | Q3 2019: $9.19 million | Q4 2019: $13.44 million | Q1 2020: -$6.01 million | Q2 2020: -$14.27 million | Q3 2020: -$29.34 million | Q4 2020: -$8.33 million | Q1 2021: -$22.05 million | Q2 2021: -$24.02 million | Q4 2021: -$30.12 million | Q1 2022: -$33.59 million | Q2 2022: -$31.70 million | Q4 2022: -$28.99 million | Q1 2023: -$37.66 million | Q2 2023: -$39.07 million | Q4 2023: -$33.41 million | Q1 2024: -$31.16 million | Q2 2024: -$22.66 million | Q4 2024: -$22.29 million | Q1 2025: -$22.64 million | Q2 2025: -$18.26 million | Q4 2025: -$11.94 million.
- Over the full 15 years of available data (2011 to 2025), ENANTA PHARMACEUTICALS INC's Net Income Loss has declined by 451.3%.
- Historical annual values: Fiscal year 2025: -$81.89 million | Fiscal year 2024: -$116.05 million | Fiscal year 2023: -$133.82 million | Fiscal year 2022: -$121.76 million | Fiscal year 2021: -$79.00 million | Fiscal year 2020: -$36.17 million | Fiscal year 2019: $46.38 million | Fiscal year 2018: $71.96 million | Fiscal year 2017: $17.71 million | Fiscal year 2016: $21.67 million | Fiscal year 2015: $78.99 million | Fiscal year 2014: $34.44 million | Fiscal year 2013: $9.63 million | Fiscal year 2012: $21.40 million | Fiscal year 2011: $23.31 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: